Want to see MDWD full AI Analyst Report?
MDWD Stock Chart & Stats
$14.23
$0.22(1.55%)
At close: 4:00 PM EDT
$14.23
$0.22(1.55%)
Day’s Range― - ―
52-Week Range$12.86 - $20.30
Previous Close$14.45
Volume52.10K
Average Volume (3M)83.89K
Market Cap
$170.54M
Enterprise Value$163.59
Total Cash (Recent Filing)$35.34M
Total Debt (Recent Filing)$9.54M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 17, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding12,910,278
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.81
Price to Sales (P/S)12.38
P/FCF Ratio-10.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.60Price Target Upside100.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$23.67M
Bulls Say, Bears Say
Bulls Say
EscharEx Phase III ProgressAdvancing the pivotal VALUE trial creates a credible path toward a second commercial product in chronic wound care. Successful execution could broaden MediWound beyond burns, diversify revenue, and support a larger long-term addressable market.
Government-backed NexoBrid ProgramsGovernment-funded development and procurement can provide non-dilutive support, validate NexoBrid for preparedness applications, and expand its use beyond traditional burn centers. These programs may create durable partner activity and additional demand.
Growing U.S. NexoBrid AdoptionRecord partner revenue, hospital unit sales, and ordering-center growth indicate improving product acceptance in the U.S. Expanding clinical utilization and distribution can strengthen NexoBrid's commercial position and provide a foundation for recurring sales.
Bears Say
Declining Revenue And Weak MarginsSharp revenue contraction and persistent margin compression show that current commercial scale is insufficient to absorb the cost base. Reliance on timing-sensitive program revenue makes results less predictable until product demand and mix improve.
Persistent Cash Burn And Operating LossesSubstantial cash consumption alongside widening operating losses limits self-funding capacity. Continued investment in trials and operations may require financing before products reach greater scale, creating dilution or liquidity risk over the medium term.
Manufacturing And Regulatory Capacity DelaysCapacity remains a structural constraint on product sales, with regulatory work delaying expanded commercial supply. Limited inventory across territories can defer revenue growth, restrict market access, and increase execution risk while demand is being developed.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $12.86 and its highest was $20.30 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $170.54M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Nov 17, 2026 which is in 84 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Aug 13, 2026. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.762 by -$0.008.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.71.
How many shares outstanding does Mediwound have?
Mediwound has 12,910,278 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.762. Following the earnings report the stock price went down -2.732%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.60 (100.98% Upside)
$28.60 (100.98% Upside)
Blogger Sentiment
Neutral
MDWD Sentiment 50%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 3.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $136.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful strategic and operational milestones — advancing EscharEx Phase III enrollment, an expanded $1.05B U.S. market assessment, a new MSA with Vericel tied to BARDA funding, government-sponsored next-generation NexoBrid programs, and strengthened U.S. commercial signals for NexoBrid. However, the company reported sharp year-over-year revenue declines (Q2 down ~45.6%, H1 down ~52.6%), substantial margin compression, rising R&D and operating losses, a notable cash decline to $36M and $20M H1 cash burn, and ongoing manufacturing capacity constraints with regulatory-tied timelines. Overall, positives around pipeline progress and government-backed programs are balanced by near-term financial weakness and execution/timing risks.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$28.60
▲(100.98% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Corbus Pharmaceuticals
―
Verrica Pharmaceuticals
―
Humacyte
―
Ownership Overview
0.65% Insiders
5.62% Mutual Funds
26.10% Other Institutional Investors
62.54% Public Companies and
Individual Investors